Rigel: Merck Serono Exercises Option In Japanese Territory (Japan)
This article was originally published in PharmAsia News
Rigel Pharmaceuticals Inc. reports that Merck KGaA's Merck Serono division exercised its option to add the Japanese territory to its Aurora kinase collaboration that includes Rigel's lead product, R763/AS703569. Rigel will receive a $3 million payment in exchange for the extended development and marketing rights. In October 2005, Rigel and Merck Serono signed a worldwide collaboration, excluding Japan, to develop R763/AS703569 and other Aurora kinase inhibitors. R763/AS703569 has exhibited anti-tumor activity against a range of cancer cell lines. (Click here for more - May Require Paid Subscription
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.